Chaoshuang Lin

Prof. Chaoshuang Lin

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
GZGuofen Zeng
Guofen Zeng
JWJialiang Wang
Jialiang Wang
YHYanlin Huang
Yanlin Huang
YLYi-Fan Lian
Yi-Fan Lian
DCDongmei Chen
Dongmei Chen
YHYuehua Huang
Yuehua Huang
Purpose: To determine the oncogenic role of the sixth subunit of chaperonin-containing tailless complex polypeptide 1 (CCT6A) in hepatocellular carcinoma (HCC) and address the correlation of CCT6A with clinicopathological characteristics and survival. Additionally, this study aimed to explore the effect of CCT6A on HCC cells and the underlying mechanisms. Methods: We searched for levels of CCT6A expression in the Oncomine database and GEPIA database, which was then validated by analyzing cancer and adjacent non-cancerous tissues of HCC patients using quantitative PCR, Western blot, and immunohistochemistry assays. The relationship between CCT6A expression and survival was analyzed from the GEPIA database and confirmed by immunohistochemistry assays of 133 HCC tissue sections. In addition, the effect of depleting CCT6A on cell proliferation was assessed by CCK-8 and colony formation assays. Cell cycle analysis, immunofluorescence assays, GSEA analysis, and cyclin D expression analyzed by Western blot were used to explore the possible underlying mechanism how dysregulated CCT6A affect the proliferation of HCC. Results: Both mRNA and protein levels of CCT6A were increased in HCC tissues. Higher CCT6A expression was significantly associated with reduced overall survival (P = 0.023). CCT6A depletion inhibited cell proliferation and downregulated cyclin D, hindering the G1-to-S phase arrest. Conclusion: CCT6A may contribute to HCC cell proliferation by accelerating the G1-to-S transition, as it maintains the expression of cyclin D. CCT6A could be considered an oncogene of HCC and could be used as a prognostic biomarker for HCC.

24 March 2019 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
YZYingfu Zeng
Yingfu Zeng
YLYiting Li
Yiting Li
ZXZhen Xu
Zhen Xu
WGWeiqiang Gan
Weiqiang Gan
LLLirong Lu
Lirong Lu
CLChaoshuang Lin
Chaoshuang Lin

1 January 2017 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
GNGang Ning
Gang Ning
YLYi-Ting Li
Yi-Ting Li
YCYou-Ming Chen
You-Ming Chen
YZYing Zhang
Ying Zhang
YZYing-Fu Zeng
Ying-Fu Zeng
CLChaoshuang Lin
Chaoshuang Lin
Objective. Up to now, little was known about the immunological changes of chronic hepatitis C (CHC) patients treated with direct-acting antiviral agents (DAAs); we try to explore the effect of DAAs on the frequency of monocytes, NK cells, and cytokines that promote their activation. Methods. 15 treatment-naive CHC patients and 10 healthy controls were recruited. Patients were examined before DAAs therapy (0 w) and at week 4 (4 w) and week 12 (12 w) of therapy. Percentage of monocytes and NK cells of the peripheral blood was analyzed by flow cytometry. Serum cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14, and sCD163 were measured by enzyme linked immunosorbent assay. Results. The frequency of CD3–CD16+CD56+ NK cells and classic CD14++CD16− monocytes decreased, while CD14+CD16+ monocytes and cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14, and sCD163 increased at 0 w compared to healthy controls. During DAAs treatment, the decreased NK cells and classic monocytes gradually increased to normal levels; the increased inflammatory monocytes and cytokines IL-12 and CXCL11 decreased to normal levels, but the increased cytokines IL-18, CXCL10, sCD14, and sCD163 still remained at high levels at 12 w though they decreased rapidly from 0 w. Conclusion. Our results showed that DAAs treatment attenuated the activation of monocytes and NK cells in CHC patients. Trial registration number is NCT03063723.

1 September 2018 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
YLYiting Li
Yiting Li
YZYingfu Zeng
Yingfu Zeng
GZGuofen Zeng
Guofen Zeng
JLJianguo Li
Jianguo Li
XZXiaohong Zhang
Xiaohong Zhang
CLChaoshuang Lin
Chaoshuang Lin

30 November 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
YCY. Chen
Y. Chen
CXChan Xie
Chan Xie
YZY. Zhang
Y. Zhang
YLY. Li
Y. Li
SES. Ehrhardt
S. Ehrhardt
CLChaoshuang Lin
Chaoshuang Lin

15 May 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
LXLi‐Xin Xiao
Li‐Xin Xiao
YCYi‐Ru Chen
Yi‐Ru Chen
PHPing Huang
Ping Huang
YMYong‐Yu Mei
Yong‐Yu Mei
CPCalvin Q. Pan
Calvin Q. Pan
CLChaoshuang Lin
Chaoshuang Lin